FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Feb 23, 2026, 16:49Unpacking Genetic Markers for Thyroid Nodule Risks – Johns Hopkins Medicine
-
Feb 23, 2026, 16:46Marco Zaccaria: Link Between Vaginal Microbiota and Uterine Fibroids Explored
-
Feb 23, 2026, 16:43Yannick Hurni: Comparative Insights on IVF Stimulation Phases
-
Feb 23, 2026, 16:38Ovarian Stroma’s Role in Infertility Treatment Explored – Science Magazine
-
Feb 22, 2026, 17:50New Research on Oocyte Quality Challenges in DOR – RBMO
-
Feb 22, 2026, 06:58Ronell Martz: Fertility Preservation CME with Maria Costantini-Ferrando
-
Feb 22, 2026, 06:25Master Embryo Transfer Techniques at EFRE Conference 2026 – EFRE
-
Feb 22, 2026, 06:11New Insights into Comorbidities in Adenomyosis Patients – RBMO
-
Feb 22, 2026, 06:02New Evidence-Based Recommendations on Infertility – ESHRE